Welcome to our dedicated page for Edgewise Therapeutics news (Ticker: EWTX), a resource for investors and traders seeking the latest updates and insights on Edgewise Therapeutics stock.
Edgewise Therapeutics, Inc. (NASDAQ: EWTX) is a clinical-stage biopharmaceutical company focused on developing novel therapeutics for muscular dystrophies and serious cardiac conditions. The Edgewise news feed on Stock Titan aggregates company announcements, press releases, and other coverage related to its clinical programs, corporate developments, and financial updates.
Investors and observers following EWTX news will see regular updates on the company’s lead product candidates. These include sevasemten, an orally administered first-in-class fast skeletal myosin inhibitor in late-stage trials for Becker and Duchenne muscular dystrophies; EDG-7500, a cardiac sarcomere modulator in Phase 2 development for hypertrophic cardiomyopathy; and EDG-15400, a cardiac sarcomere modulator in Phase 1 development for heart failure. News items often describe trial progress, such as enrollment status, interim results, and plans for pivotal studies, as well as interactions with regulators.
The Edgewise news stream also features corporate and governance updates, including board and executive appointments, inducement equity grants under Nasdaq Listing Rules, participation in major healthcare and investor conferences, and periodic financial results. These disclosures provide context on how the company is building its organization and funding its research and development activities.
By monitoring this page, readers can review historical and recent EWTX news related to muscular dystrophy and cardiovascular programs, clinical milestones, and corporate actions as reported by the company in its public communications.
Edgewise Therapeutics (NASDAQ: EWTX) has appointed Dr. Joanne M. Donovan as Chief Medical Officer, aiming to bolster its clinical and regulatory strategies for its lead product, EDG-5506, targeting Duchenne and Becker muscular dystrophy (DMD and BMD). Dr. Donovan brings extensive experience in rare disease clinical development, having previously led programs from discovery to approval. EDG-5506 represents a novel treatment approach for these muscle disorders, currently in Phase 1 clinical trials, with topline data expected soon.
Edgewise Therapeutics, Inc. (NASDAQ: EWTX) has successfully closed its initial public offering (IPO) of 12,650,000 shares, including 1,650,000 shares from underwriters' option, at $16.00 per share. This results in gross proceeds of $202.4 million. Trading started on March 26, 2021. J.P. Morgan, Goldman Sachs, and SVB Leerink served as joint book-running managers for the offering. Edgewise focuses on developing treatments for rare muscle disorders and has a proprietary drug discovery platform aimed at muscle biology.
Edgewise Therapeutics, Inc. (NASDAQ: EWTX) has priced its initial public offering (IPO) of 11,000,000 shares at $16.00 each, aiming for gross proceeds of $176 million. The shares will trade on the Nasdaq Global Select Market starting March 26, 2021, with the offering closing on March 30, 2021, pending customary conditions. The underwriters also have a 30-day option to purchase an additional 1,650,000 shares. J.P. Morgan, Goldman Sachs, and SVB Leerink are leading the offering.